Meloxicam Tillomed Laboratories

Meloxicam, the active ingredient in Meloxicam Tillomed Laboratories, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral dosage form for oral use. It is indicated for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal pain.

GNH USA supplies Meloxicam Tillomed Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that reduces inflammation and pain in several musculoskeletal disorders.

- Osteoarthritis: alleviates joint pain and improves functional mobility. - Rheumatoid arthritis: decreases synovial inflammation and limits disease‑related joint damage. - Ankylosing spondylitis: reduces spinal stiffness and chronic back pain. - Acute pain: provides rapid relief of short‑term inflammatory pain such as post‑operative or injury‑related discomfort.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Peripheral edema: swelling of the lower limbs. - Elevated blood pressure. - Skin rash or pruritus.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Cardiovascular events such as myocardial infarction or stroke. - Hepatic enzyme elevation or liver injury. - Severe skin reactions (e.g., Stevens‑Johnson syndrome). - Renal impairment or acute kidney injury. - Anaphylactic or severe hypersensitivity reactions.

Before initiating meloxicam, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Cardiovascular risk assessment: consider underlying heart disease before use. - Renal function monitoring: check serum creatinine and eGFR periodically. - Gastrointestinal ulcer risk: avoid in patients with a history of peptic ulcer disease unless gastro‑protective therapy is provided. - Hepatic monitoring: assess liver enzymes in patients with liver disease. - Hypersensitivity screening: discontinue if signs of allergic reaction appear. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Meloxicam can alter the pharmacokinetics or pharmacodynamics of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Lithium: reduced renal clearance leading to toxicity. - Methotrexate: enhanced toxicity, especially at high doses. - Cyclosporine: heightened nephrotoxicity. - Diuretics (loop or thiazide): may impair renal function.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: additive risk of gastrointestinal bleeding. - ACE inhibitors or ARBs: potential reduction in antihypertensive effect and renal function. - Oral hypoglycemics: may affect blood glucose control. - Corticosteroids: increased risk of ulceration and bleeding.